Concord Biotech Ltd. (CONCORDBIO): Concord Biotech Share Price rises 5.71% as stock gains today
- September 21, 2026
- Posted by: Harsh Piplani
- Category: News
Concord Biotech Share Price rose to Rs 1,579.25 today, up 5.71% from the previous close of Rs 1,493.90, with the company’s market capitalisation at Rs 15,628.61 crore. The move places Concord Biotech Ltd. among the notable stocks in news in the healthcare space, and the supplied data confirms the price event without establishing a company-specific catalyst. For readers tracking Concord Biotech Share Price Today, the key takeaway is simple: the stock opened at Rs 1,530.90, touched Rs 1,585.00 and Rs 1,512.70 during the session, and finished well above the prior close. Univest is covering the rise with a factual lens on price action, valuation, industry context and peer comparison so investors can understand what changed today and what still needs monitoring.
At Rs 1,579.25, Concord Biotech Share Price also sits alongside a turnover of Rs 2.77 crore, which is a factual traded-value metric and should be read only as part of the day’s market update. In this Concord Biotech Stock News note, the focus remains on verified numbers, not assumptions. Univest is highlighting the move because the share price rise comes at a valuation that is already higher than the same-industry median, making the day’s market update relevant for both short-term tracking and broader fundamental analysis.
Concord Biotech Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,579.25 |
| Previous Close | Rs 1,493.9 |
| Today's Move | Rs 85.35 (+5.71%) |
| Open | Rs 1,530.9 |
| High | Rs 1,585 |
| Low | Rs 1,512.7 |
| Turnover | Rs 2.77 crore |
| Market Capitalisation | Rs 15,628.61 crore |
| Market Cap Category | Mid Cap |
Concord Biotech Ltd. (CONCORDBIO) rose to Rs 1,579.25 from the previous close of Rs 1,493.9, a move of Rs 85.35 or 5.71%. The stock opened at Rs 1,530.9, reached a high of Rs 1,585, recorded a low of Rs 1,512.7.
Concord Biotech Share Price today closed at Rs 1,579.25, higher by Rs 85.35 or 5.71% versus the previous close of Rs 1,493.90. The stock traded between Rs 1,512.70 and Rs 1,585.00 after opening at Rs 1,530.90. This confirms a clear same-day price rise for Concord Biotech Ltd., with the session ending near the day’s upper range and above the opening level. The event is relevant for Concord Biotech Share Price Today searches because it reflects a measurable share price gain and a fresh stock update, but the supplied data does not establish a company-specific catalyst.
For readers looking at Concord Biotech Share Price Live or Concord Biotech Share Price Update, the movement is best understood as a verified price action development. Univest is using the same data point set that the market has already seen: current price, previous close, day change, open, high, low, turnover and market cap. That makes the rise suitable for event-led stock news coverage without extending into unsupported claims about why the stock moved.
Concord Biotech Ltd. (CONCORDBIO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,628.61 crore |
| P/E Ratio | 56.75x |
| P/B Ratio | 7.54x |
| ROE | 13.54% |
| ROCE | 18.04% |
| EPS | Rs 26.32 |
| Book Value Per Share | Rs 198.2 |
| Dividend Yield | 0.51% |
Concord Biotech Ltd. (CONCORDBIO) fundamental metrics show P/E 56.75x, P/B 7.54x, ROE 13.54%, ROCE 18.04%. These figures provide context only and are not a buy or sell signal.
Concord Biotech Ltd. has a market capitalisation of Rs 15628.61 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 56.75x, P/B at 7.54x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 13.54% and ROCE of 18.04%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 26.32, book value per share of Rs 198.2, dividend yield of 0.51%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.87x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 56.75x |
| Benchmark Median P/E | 32.87x |
| Benchmark Average P/E | 48.77x |
| Benchmark P/E Range | 3.4x to 683.5x |
| Company P/B Ratio | 7.54x |
| Benchmark Median P/B | 3.08x |
| Company ROE | 13.54% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 18.04% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 15,628.61 crore |
| Benchmark Median Market Cap | Rs 701.78 crore |
Concord Biotech Ltd. (CONCORDBIO) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Concord Biotech Ltd. (CONCORDBIO) has a P/E ratio of 56.75x, which is above the benchmark median of 32.87x, a difference of +72.65%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Concord Biotech Ltd. (CONCORDBIO) has a ROE of 13.54%, which is above the benchmark median of 11.7%, a difference of +15.73%. Concord Biotech Ltd. (CONCORDBIO) has a ROCE of 18.04%, which is above the benchmark median of 13.46%, a difference of +34.03%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,40,397.93 | 36.41 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,48,664.42 | 85.01 | 14.08 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,82,738.23 | 83.79 | 20.36 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,012.19 | 25.48 | 4.27 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,10,793.75 | 32.87 | 3.15 | 11.83 | 16 |
Concord Biotech Ltd. (CONCORDBIO) has a P/E ratio of 56.75x compared with the displayed peer median of 36.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 13.54% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 18.04% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Concord Biotech Ltd. (CONCORDBIO) has a market capitalisation of Rs 15,628.61 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Concord Biotech
- Concord Biotech Share Price rose 5.71% today to Rs 1,579.25 after closing above the previous close of Rs 1,493.90.
- The stock traded between Rs 1,512.70 and Rs 1,585.00, with an opening price of Rs 1,530.90 and a final close near the day’s upper end.
- Market capitalisation stands at Rs 15,628.61 crore, which is above the industry average of Rs 13,926.75 crore in the same-industry snapshot.
- Concord Biotech’s P/E ratio of 56.75 and P/B ratio of 7.54 are above the same-industry median benchmarks of 32.87 and 3.08.
- ROE of 13.54% and ROCE of 18.04% are both above the same-industry median levels, while the dividend yield is 0.51%.
About Concord Biotech
Concord Biotech Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data does not provide a segment breakdown, revenue mix or product list, so the company context here is kept to verified identifiers and financial positioning. In that framework, the business is part of a sector where earnings quality, valuation multiples and return ratios are often compared closely by market participants.
What stands out in the available data is the scale of the company and the richness of the valuation profile. Concord Biotech Share Price today is being tracked alongside a market capitalisation of Rs 15,628.61 crore, an EPS of Rs 26.32, book value of Rs 198.20 and dividend yield of 0.51%. These figures make the company easy to place within the pharmaceutical universe even without adding unsupported business details. For Univest readers, that is useful because Concord Biotech Stock News can then be read as both a price event and a fundamentals-led market update.
Track Concord Biotech Share Price on Univest
Use Concord Biotech Ltd. (CONCORDBIO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Users can track Concord Biotech Share Price on Univest for live share price updates, market cap, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest also helps readers compare Concord Biotech Share Price Today with related healthcare peers, sector benchmarks and company financial metrics in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Concord Biotech Share Price rising today?
Ans. Concord Biotech Share Price rose 5.71% to Rs 1,579.25 today, with the session high at Rs 1,585.00. The supplied data confirms the price event, but it does not establish a company-specific catalyst.
What is Concord Biotech Share Price today?
Ans. Concord Biotech Share Price today is Rs 1,579.25. It moved up Rs 85.35 from the previous close of Rs 1,493.90, which makes it a clear same-day share price rise. The previous close was Rs 1,493.9.
What is the market capitalisation of Concord Biotech?
Ans. Concord Biotech’s market capitalisation is Rs 15,628.61 crore. That places the company above the same-industry average market cap of Rs 13,926.75 crore in the benchmark set used here. The company operates in the Healthcare sector.
Is Concord Biotech expensive compared with peers?
Ans. Concord Biotech’s P/E of 56.75 and P/B of 7.54 are above the same-industry median levels. That places the stock on the richer side of the peer set on valuation. Comparable listed companies include Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd..
How do Concord Biotech’s returns compare with the industry?
Ans. Concord Biotech reports ROE of 13.54% and ROCE of 18.04%. Both are above the same-industry median benchmarks of 11.70% and 13.46%, giving the stock a stronger return profile in this dataset.
What do EPS, book value and dividend yield show for Concord Biotech?
Ans. EPS is Rs 26.32, book value is Rs 198.20 and dividend yield is 0.51%. These figures show earnings per share, accounting net worth per share and the current payout reference.
How did Concord Biotech trade during the day?
Ans. Concord Biotech opened at Rs 1,530.90, hit a high of Rs 1,585.00 and a low of Rs 1,512.70, before closing at Rs 1,579.25. The move kept the stock above the previous close.
Which sector and industry does Concord Biotech belong to?
Ans. Concord Biotech belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. Its same-industry benchmark covers 204 companies, which helps place the valuation and return ratios in context. The stock belongs to the Healthcare sector.
